Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Gleevec's (Novartis) other use...
December 23, 2008
FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer | www.therapeuticsdaily.com
This valuable agent can now be used as an adjuvant (preventative) fashion in patients with gastrointestinal stroma tumors (GIST)
-
BMS & Exelixis: A bargain?? The cost appears high?
December 16, 2008
Bristol-Myers, Biotech Firm to Develop Cancer Drugs | online.wsj.com
"Under the agreement, Bristol-Myers will pay Exelixis $195 million now and another $45 million in 2009 to codevelop the drugs, known as XL184 and XL281"
-
Millennium's Velcade, truly a blockbuster!
December 10, 2008
Blood-Cancer Drug Hits $1 Billion | online.wsj.com
Despite my initial reservations Re: too frequent administrations, this is a blockbuster that is not only effective but relatively non toxic.
-
Perhaps the proble is not the British but......
December 4, 2008
British Balance Benefit vs. Cost of Latest Drugs | www.nytimes.com
Britain is reticent to pay for Sutent which will prolong the patients life by months.....
-
Clinical trials held abroad... Implications?
December 2, 2008
Scrutiny Grows of Drug Trials Abroad | online.wsj.com
This article pertains to quality, accrual and safety, but in addition....
-
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Scientists recommend 'black box' for Avastin | www.fiercepharma.com
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
-
GSK's Promacta for ITP: a winner1
November 24, 2008
PROMACTA (Brand Name Drug) FDA approval 11/20/08 | www.accessdata.fda.gov
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
-
Vandetanib (Astra Zeneca): too long at the "Fair?"
November 19, 2008
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
-
Erbitux in Lung Ca- now to predict who will get the skin rash.
November 17, 2008
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.drugs.com
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a rash live significantly longer. NOW let's predict who will get the rash! 25+% percent developed a rash. Who are they?
-
Roche's Tarceva offers a competitor to Lilly's Alimta
November 11, 2008
Roche Says Tarceva Data Promising | online.wsj.com
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
-
Increased use of Zevalin, Bayer ( & by osmosis Bexxar, GSK) in low grade lymphomas
November 11, 2008
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma | jco.ascopubs.org
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.
-
Is Pharma's Head in the Sand??
November 10, 2008
Pharma need not worry too much about President Obama | www.biovalley.ch
The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??
-
GSK to cut sales force , but......
November 6, 2008
Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably
-
Avastin in Glioblastomas: I believe approval will be....
November 6, 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.
-
A target may well decrease the market for EGFR inhibitors (Erbitux & Vectibix) in colon cancer (CRC)
October 24, 2008
Targeting EGFR in Colorectal Cancer | content.nejm.org
Measuring mutated K-RAS will show who will NOT respond to ImClone's Erbitux or Amgen's Vectibix. Thus to use either in CRC will not be particularly effective.
-
October 23, 2008
Panel Calls for Vaccine for Adult Smokers | online.wsj.com
31 million more doses of Pneumovax yearly in the US??
-
GVAX: Why did it fail? Let me list the possible ways......
October 21, 2008
Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.
-
Thyroid cancer: When it rains it pours
October 15, 2008
Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
as per an accompanying editorial "In conclusion, it is particularly gratifying that years of research in tumor biology and drug development have coalesced. Translation of these research advances into therapeutic benefits for patients with refractory thyroid cancer, and a related paradigm shift in the treatment of these tumors, appear not far off. Support of well-designed clinical trials will be critical to realizing these benefits in a timely way"
-
Genetically determined cancer therapy: It will be a wash.
October 15, 2008
Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Genetic determinants will decrease use of some drugs due to mutations such as Kras which indicate less chance of response and thus the chemo agents will not be used.
-
Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
October 8, 2008
Genentech Set Back by Cancer-Drug Study | online.wsj.com
The primary goal was improved survival- NOT REACHED!!
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.